Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Whitehead

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Bioorganic & Medicinal Chemistry Letters|October 28, 2008
2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase)Joseph S Warmus, Cathlin Flamme, Lu Yan Zhang, et al.
Neoplasia (New York, N.Y.)|April 9, 2014
KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated β-TrCP1 degradationShirish Shukla, Uday Sankar Allam, Aarif Ahsan, et al.
Nature Structural & Molecular Biology|November 16, 2004
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibitionJeffrey F Ohren, Huifen Chen, Alexander Pavlovsky, et al.
Bioorganic & Medicinal Chemistry Letters|April 16, 2013
Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitorsMark S Plummer, Joseph Cornicelli, Howard Roark, et al.
Bioorganic & Medicinal Chemistry Letters|April 20, 2013
Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacyMark S Plummer, Joseph Cornicelli, Howard Roark, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Bioorganic & Medicinal Chemistry Letters|October 28, 2008
2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase)Joseph S Warmus, Cathlin Flamme, Lu Yan Zhang, et al.
Neoplasia (New York, N.Y.)|April 9, 2014
KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated β-TrCP1 degradationShirish Shukla, Uday Sankar Allam, Aarif Ahsan, et al.
Nature Structural & Molecular Biology|November 16, 2004
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibitionJeffrey F Ohren, Huifen Chen, Alexander Pavlovsky, et al.
Bioorganic & Medicinal Chemistry Letters|April 16, 2013
Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitorsMark S Plummer, Joseph Cornicelli, Howard Roark, et al.
Bioorganic & Medicinal Chemistry Letters|April 20, 2013
Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacyMark S Plummer, Joseph Cornicelli, Howard Roark, et al.
Pageof 3